• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

    2.850 -0.010 (-0.35%)
    Streaming Delayed Price Updated: 9:39 AM EDT, Aug 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 563,858
    Open 2.870
    Bid (Size) 2.840 (300)
    Ask (Size) 2.850 (500)
    Prev. Close 2.860
    Today's Range 2.740 - 2.920
    52wk Range 2.810 - 8.590
    Shares Outstanding 93,500,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Myriad Genetics Q2 Earnings Call Highlights ↗
    Myriad Genetics (NASDAQ:MYGN) reported second-quarter 2026 revenue of $190.7 million, down 11% from a year earlier, as a 1% decline in total test volume and a 9% decrease in revenue per test weighed on... 
    Via MarketBeat
    Topics Artificial Intelligence Earnings
    Top movers in Friday's session ↗
    Via Chartmill

    Performance

    YTD
    -53.6%
    -53.6%
    1 Month
    -52.7%
    -52.7%
    3 Month
    -42.3%
    -42.3%
    6 Month
    -47.9%
    -47.9%
    1 Year
    -28.4%
    -28.4%

    More News

    Read More
    News headline image
    Why Myriad Genetics (MYGN) Shares Are Falling Today
    Via StockStory
    Topics Artificial Intelligence
    Top stock movements in today's session. ↗
    Via Chartmill
    Myriad Genetics (NASDAQ:MYGN) Plunges 26% After Fiscal Q2 Revenue and EPS Miss, Slashes Full-Year Guidance ↗
    Via Chartmill
    Gapping stocks in Friday's session ↗
    Via Chartmill
    Friday's pre-market session: top gainers and losers ↗
    Via Chartmill
    Thursday's after hours session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Myriad Genetics (NASDAQ:MYGN) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 28.6%
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    3 Unprofitable Stocks That Fall Short
    Via StockStory
    News headline image
    Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    3 Reasons MYGN is Risky and 1 Stock to Buy Instead
    Via StockStory
    News headline image
    Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
    Via StockStory
    News headline image
    Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today
    Via StockStory
    News headline image
    Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds
    Via StockStory
    Topics Bankruptcy
    News headline image
    3 High-Flying Stocks We’re Skeptical Of
    Via StockStory
    News headline image
    Myriad Genetics Names Raj Jampa as New Chief Technology Officer
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
    From Myriad Genetics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Myriad Genetics, Inc. - Common Stock publicly traded?
    Yes, Myriad Genetics, Inc. - Common Stock is publicly traded.
    What exchange does Myriad Genetics, Inc. - Common Stock trade on?
    Myriad Genetics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Myriad Genetics, Inc. - Common Stock?
    The ticker symbol for Myriad Genetics, Inc. - Common Stock is MYGN on the Nasdaq Stock Market
    What is the current price of Myriad Genetics, Inc. - Common Stock?
    The current price of Myriad Genetics, Inc. - Common Stock is 2.850
    When was Myriad Genetics, Inc. - Common Stock last traded?
    The last trade of Myriad Genetics, Inc. - Common Stock was at 08/03/26 09:39 AM ET
    What is the market capitalization of Myriad Genetics, Inc. - Common Stock?
    The market capitalization of Myriad Genetics, Inc. - Common Stock is 266.48M
    How many shares of Myriad Genetics, Inc. - Common Stock are outstanding?
    Myriad Genetics, Inc. - Common Stock has 266M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.